Frontlight ResearchEarly access
Psoriatic arthritis trials in Belgium
6 of 8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 3Not yet taking people in BelgiumContinuation Study of Zasocitinib in Adults With Psoriatic Arthritis
- Where
- Anderlecht, Brussels, Genk, Gent, Liège
- Age
- 18 years and over
- People
- 1,182 worldwide
- Run by
- Takeda
See details and how to joinNCT07286058 · EU 2025-522586-30-00 - Phase 4Not yet taking people in BelgiumAn open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
- Where
- Brugge, Genk, Gent, Liège, Mons
- People
- 339 worldwide
- Run by
- Novartis Pharma AG
See details and how to joinNCT04638647 · EU 2023-504417-67-00 - Phase 3CompletedA Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis
- Where
- Gent, Leuven, Sint-Lambrechts-Woluwe
- Age
- 1 year to 18 years
- People
- 190 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT03773965 · EU 2023-506131-15-00 - Phase 3Taking peopleA Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Where
- Gent, Jette, Leuven
- Age
- 3 years to 64 years
- People
- 196 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06663332 · EU 2023-509560-16-00 - Phase 3CompletedApremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
- Where
- Antwerp, Gent, Liège
- Age
- 5 years to 17 years
- People
- 60 worldwide
- Run by
- Amgen
See details and how to joinNCT04804553 · EU 2023-503435-17-00 - Phase 4Taking peopleA Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis
- Where
- Leuven, Ghent University Hospital
- Age
- 18 years and over
- People
- 100 worldwide
- Run by
- CARE ARTHRITIS LTD.
See details and how to joinNCT06454188 · EU 2023-510242-24-00